Literature DB >> 27860467

Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities.

Helga Radner1, Kazuki Yoshida2, Sara Tedeschi3, Paul Studenic4, Michelle Frits3, Christine Iannaccone3, Nancy A Shadick3, Michael Weinblatt3, Daniel Aletaha4, Josef S Smolen4, Daniel H Solomon3.   

Abstract

OBJECTIVE: To quantify differences and determine the factors contributing to the difference in patient global assessment of rheumatoid arthritis (RA) disease activity (PtGA) between RA patients with multiple morbidities (RA-MM) and those with RA only.
METHODS: We compared the PtGA between RA-MM patients and those with RA only, followed up in a longitudinal cohort (n = 1,040). In analyses performed on RA-MM patients (n = 575) and those with RA only (matched for swollen joint count, tender joint count, evaluator global assessment, and disease duration), the mean difference in PtGA (ΔPtGA) between the 2 groups was assessed. The contribution of patient characteristics to the explained variation of ΔPtGA in the matched cohort was calculated as semipartial R2 and summarized as the percentage of the total R2 in linear regression models.
RESULTS: RA-MM patients reported higher (or worse) PtGA, with an increased PtGA associated with more morbidities (P for linear trend < 0.01); this relationship remained significant after adjustment for disease activity, age, and disease duration. After matching 294 RA-MM patients to those with RA only, the pairwise comparison of mean PtGA (on a scale of 0-100 mm) was significantly higher (worse) for RA-MM patients (mean ± SD 30.5 ± 24.3) versus those with RA only (25.6 ± 22.9) (mean ΔPtGA 4.9 ± 26.7; P < 0.01 by paired t-test). Variables uniquely contributing to ΔPtGA were fatigue (18%), pain (17%), and modified Health Assessment Questionnaire scores (9%).
CONCLUSION: In RA patients with multiple morbidities, the perception of RA disease activity as measured by the PtGA might be impacted by the burden of multiple diseases in one individual. RA-MM patients have higher (worse) levels of PtGA scores compared to patients with RA only. The difference in PtGA is mainly explained by differences in fatigue and pain.
© 2016, American College of Rheumatology.

Entities:  

Mesh:

Year:  2017        PMID: 27860467     DOI: 10.1002/art.39988

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  7 in total

1.  Responsiveness of Patient-Reported Outcomes Measurement Information System Measures in Rheumatoid Arthritis Patients Starting or Switching a Disease-Modifying Antirheumatic Drug.

Authors:  Alyssa Wohlfahrt; Clifton O Bingham; Wendy Marder; Kristine Phillips; Marcy B Bolster; Larry W Moreland; Zhi Zhang; Tuhina Neogi; Yvonne C Lee
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-04       Impact factor: 4.794

2.  Predictors and the optimal duration of sustained remission in rheumatoid arthritis.

Authors:  Sibel Yilmaz-Oner; Ummugulsum Gazel; Meryem Can; Pamir Atagunduz; Haner Direskeneli; Nevsun Inanc
Journal:  Clin Rheumatol       Date:  2019-07-03       Impact factor: 2.980

3.  Disease and management beliefs of elderly patients with rheumatoid arthritis and comorbidity: a qualitative study.

Authors:  Marloes van Onna; Betül Öztürk; Mirian Starmans; Ralph Peeters; Annelies Boonen
Journal:  Clin Rheumatol       Date:  2018-06-09       Impact factor: 2.980

4.  Association between pain phenotype and disease activity in rheumatoid arthritis patients: a non-interventional, longitudinal cohort study.

Authors:  P M Ten Klooster; N de Graaf; H E Vonkeman
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156

5.  Remission or Not Remission, That's the Question: Shedding Light on Remission and the Impact of Objective and Subjective Measures Reflecting Disease Activity in Rheumatoid Arthritis.

Authors:  Alen Brkic; Katarzyna Łosińska; Are Hugo Pripp; Mariusz Korkosz; Glenn Haugeberg
Journal:  Rheumatol Ther       Date:  2022-09-21

6.  Limiting factors to Boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis.

Authors:  Serena Bugatti; Ludovico De Stefano; Antonio Manzo; Garifallia Sakellariou; Blerina Xoxi; Carlomaurizio Montecucco
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-22       Impact factor: 5.346

7.  Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

Authors:  Vibeke Norvang; Joseph Sexton; Eirik K Kristianslund; Inge C Olsen; Till Uhlig; Gunnstein Bakland; Frode Krøll; Erik Rødevand; Ada Wierød; Tore K Kvien; Josef S Smolen; Daniel Aletaha; Espen A Haavardsholm
Journal:  RMD Open       Date:  2018-10-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.